Drug-induced liver injury in COVID-19 treatment: Incidence, mechanisms and clinical management
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Drug-induced liver injury in COVID-19 treatment: Incidence, mechanisms and clinical management
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-11-28
DOI
10.3389/fphar.2022.1019487
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis
- (2022) Wen Wen et al. ANNALS OF MEDICINE
- Remdesivir-Induced Liver Injury in a COVID-Positive Newborn
- (2022) Manjit Kaur et al. INDIAN JOURNAL OF PEDIATRICS
- Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study
- (2022) Figen Öztürk Ergür et al. Sao Paulo Medical Journal
- Potential Effects of COVID-19 on Cytochrome P450-Mediated Drug Metabolism and Disposition in Infected Patients
- (2021) Subrata Deb et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Interaction of Remdesivir with Clinically Relevant Hepatic Drug Uptake Transporters
- (2021) Anne T. Nies et al. Pharmaceutics
- Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice
- (2021) Marina Villanueva-Paz et al. Antioxidants
- ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury
- (2021) Naga P. Chalasani et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Liver and kidney function in patients with Covid‐19 treated with remdesivir
- (2021) Sylvia A. Laar et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study
- (2021) Albert Prats-Uribe et al. BMJ-British Medical Journal
- Comparative Hepatic and Intestinal Efflux Transport of Statins
- (2021) Feng Deng et al. DRUG METABOLISM AND DISPOSITION
- Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
- (2021) Florence Ader et al. LANCET INFECTIOUS DISEASES
- Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data
- (2021) Huilin Tang et al. International Journal of Clinical Pharmacy
- Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics
- (2021) Csilla Ambrus et al. Scientific Reports
- Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial
- (2021) Chang Chen et al. Frontiers in Pharmacology
- An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
- (2021) Florence Ader et al. CLINICAL MICROBIOLOGY AND INFECTION
- Safety of Remdesivir for Patients 80 Years of Age or Older with Coronavirus Disease 2019 (COVID-19)
- (2021) Osamu Kanai et al. DRUGS & AGING
- Molecular Networking for Drug Toxicities Studies: The Case of Hydroxychloroquine in COVID-19 Patients
- (2021) Pierre-Jean Ferron et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Evaluation of Hepatic Biochemical Parameters during Antiviral Treatment in COVID-19 Patients
- (2021) Felicia Marc et al. Biology-Basel
- Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
- (2020) Philippe Colson et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
- (2020) Nanshan Chen et al. LANCET
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- A pneumonia outbreak associated with a new coronavirus of probable bat origin
- (2020) Peng Zhou et al. NATURE
- Clinical Characteristics of Coronavirus Disease 2019 in China
- (2020) Wei-jie Guan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Case Report: Hepatotoxicity Associated with the Use of Hydroxychloroquine in a Patient with Novel Coronavirus Disease (COVID-19)
- (2020) Melissa Barreto Falcão et al. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
- Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19
- (2020) Christopher R. Piszczatoski et al. ANNALS OF PHARMACOTHERAPY
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- What do we know about remdesivir drug interactions?
- (2020) Katherine Yang CTS-Clinical and Translational Science
- Liver Biochemistries in Hospitalized Patients With COVID‐19
- (2020) Patricia P. Bloom et al. HEPATOLOGY
- Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis
- (2020) Jing Yang et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression
- (2020) Dan Zhou et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): a simplified summary
- (2020) Mohamed A. Hendaus JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- COVID-19: Abnormal liver function tests
- (2020) Qingxian Cai et al. JOURNAL OF HEPATOLOGY
- Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
- (2020) Zhen Zhu et al. JOURNAL OF INFECTION
- Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis
- (2020) Jieyun Zhu et al. JOURNAL OF MEDICAL VIROLOGY
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
- (2020) Yeming Wang et al. LANCET
- Liver impairment in COVID‐19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China
- (2020) Yafei Zhang et al. LIVER INTERNATIONAL
- Clinical characteristics of non‐ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study
- (2020) Hansheng Xie et al. LIVER INTERNATIONAL
- Lopinavir–ritonavir in severe COVID-19
- (2020) Hannah Stower NATURE MEDICINE
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
- (2020) Jason D. Goldman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
- (2020) Bin Cao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Compassionate Use of Remdesivir for Patients with Severe Covid-19
- (2020) Jonathan Grein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Remdesivir: Review of pharmacology, pre‐clinical data and emerging clinical experience for COVID‐19
- (2020) Sarah CJ Jorgensen et al. PHARMACOTHERAPY
- Delayed Initiation of Remdesivir in a COVID‐19‐Positive Patient
- (2020) Emily Hillaker et al. PHARMACOTHERAPY
- Liver injury in COVID-19: The current evidence
- (2020) Saleh A Alqahtani et al. United European Gastroenterology Journal
- Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19
- (2020) Richard T. Eastman et al. ACS Central Science
- Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro
- (2020) Jia Liu et al. Cell Discovery
- Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis
- (2020) Ren Mao et al. Lancet Gastroenterology & Hepatology
- Liver injury in COVID-19: management and challenges
- (2020) Chao Zhang et al. Lancet Gastroenterology & Hepatology
- Clinical Features of COVID-19-Related Liver Functional Abnormality
- (2020) Zhenyu Fan et al. Clinical Gastroenterology and Hepatology
- Drug-induced liver injury in a COVID-19 patient: potential interaction of remdesivir with P-glycoprotein inhibitors
- (2020) Emiel Leegwater et al. CLINICAL INFECTIOUS DISEASES
- Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment
- (2020) Vicki Osborne et al. DRUG SAFETY
- Quantitative assessment of non-point source pollution load of PN/PP based on RUSLE model: a case study in Beiluo River Basin in China
- (2020) Gai-rui Hao et al. ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
- Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis
- (2020) Praveen Kumar-M et al. Hepatology International
- Using thin film freezing to minimize excipients in inhalable tacrolimus dry powder formulations
- (2020) Sawittree Sahakijpijarn et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
- (2020) Alexandre B. Cavalcanti et al. NEW ENGLAND JOURNAL OF MEDICINE
- Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status
- (2020) Spinello Antinori et al. PHARMACOLOGICAL RESEARCH
- Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease
- (2020) Michael J. Satlin et al. PLoS One
- Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients
- (2020) Lu Li et al. Drug Design Development and Therapy
- Drug induced liver injury: an update
- (2020) Miren Garcia-Cortes et al. ARCHIVES OF TOXICOLOGY
- Remdesivir against COVID-19 and Other Viral Diseases
- (2020) Jakob J. Malin et al. CLINICAL MICROBIOLOGY REVIEWS
- Remdesivir: First Approval
- (2020) Yvette N. Lamb DRUGS
- Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial
- (2020) Yan Lou et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Interaction of Hydroxychloroquine with Pharmacokinetically Important Drug Transporters
- (2020) Johanna Weiss et al. Pharmaceutics
- Pharmacogenomics of COVID-19 therapies
- (2020) Takuto Takahashi et al. npj Genomic Medicine
- Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment
- (2020) Fiona Marra et al. DRUGS IN R&D
- Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications
- (2020) Jaykaran Charan et al. Expert Review of Clinical Pharmacology
- Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
- (2020) Zarir F. Udwadia et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Clinical Pharmacology in Diuretic Use
- (2019) David H. Ellison Clinical Journal of the American Society of Nephrology
- Effects of dexamethasone to reverse decreased hepatic midazolam metabolism in rats with acute renal failure
- (2019) Masami Doi et al. XENOBIOTICA
- Drug-induced liver injury
- (2019) Raul J. Andrade et al. Nature Reviews Disease Primers
- Autoimmune Hepatitis—Immunologically Triggered Liver Pathogenesis—Diagnostic and Therapeutic Strategies
- (2019) Elisabeth Sucher et al. Journal of Immunology Research
- MRP2 Inhibition by HIV Protease Inhibitors in Rat and Human Hepatocytes: A Quantitative Confocal Microscopy Study
- (2018) Nico Holmstock et al. DRUG METABOLISM AND DISPOSITION
- The devil's in the dosing: severe drug-induced liver injury in a hydroxychloroquine-naive patient with subacute cutaneous lupus erythematosus and porphyria cutanea tarda
- (2018) B Sunkara et al. LUPUS
- HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome
- (2017) Shu Su et al. JOURNAL OF MEDICAL VIROLOGY
- Effects of Combined Alcohol and Anti-HIV Drugs on Cellular Stress Responses in Primary Hepatocytes and Hepatic Stellate and Kupffer Cells
- (2015) Jay Hu et al. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
- Drug-Induced Liver Injury
- (2015) Kurt Fisher et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- In vitro interaction of clopidogrel and its hydrolysate with OCT1, OCT2 and OAT1
- (2014) Liping Li et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Mechanisms of Drug-induced Liver Injury
- (2013) Liyun Yuan et al. Clinics in Liver Disease
- The SLCO (former SLC21) superfamily of transporters
- (2013) Bruno Hagenbuch et al. MOLECULAR ASPECTS OF MEDICINE
- Early Identification of Clinically Relevant Drug Interactions With the Human Bile Salt Export Pump (BSEP/ABCB11)
- (2013) Jenny M. Pedersen et al. TOXICOLOGICAL SCIENCES
- Case Definition and Phenotype Standardization in Drug-Induced Liver Injury
- (2011) G P Aithal et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse
- (2011) Markus R Meyer et al. PHARMACOGENOMICS
- Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes
- (2010) Zhi-wei Ye et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays
- (2010) Vesna Munić et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Membrane transporters in drug development
- (2010) NATURE REVIEWS DRUG DISCOVERY
- HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms
- (2010) Ruben C. Hartkoorn et al. Pharmacogenetics and Genomics
- Long-term virus-induced alterations of CYP3A-mediated drug metabolism: a look at the virology, immunology and molecular biology of a multi-faceted problem
- (2009) Maria A Croyle Expert Opinion on Drug Metabolism & Toxicology
- Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events
- (2009) Craig Lammert et al. HEPATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now